• 1
    Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004; 239: 818827.
  • 2
    Imamura H, Seyama Y, Kokudo N, et al. Single and multiple resections of multiple hepatic metastases of colorectal origin. Surgery. 2004; 135: 508517.
  • 3
    Stewart GD, O'Suilleabhain CB, Madhavan KK, Wigmore SJ, Parks RW, Garden OJ. The extent of resection influences outcome following hepatectomy for colorectal liver metastases. Eur J Surg Oncol. 2004; 30: 370376.
  • 4
    Takahashi S, Inoue K, Konishi M, Nakagouri T, Kinoshita T. Prognostic factors for poor survival after repeat hepatectomy in patients with colorectal liver metastases. Surgery. 2003; 133: 627634.
  • 5
    Bines SD, Doolas A, Jenkins L, Millikan K, Roseman DL. Survival after repeat hepatic resection for recurrent colorectal hepatic metastases. Surgery. 1996; 120: 591596.
  • 6
    Mijnhout GS, Hooft L, van Tulder MW, Deville WL, Teule GJ, Hoekstra OS. How to perform a comprehensive search for FDG-PET literature. Eur J Nucl Med. 2000; 27: 9197.
  • 7
    Mijnhout GS, Riphagen II, Hoekstra OS. Update of the FDG PET search strategy. Nucl Med Commun. 2004; 25: 11871189.
  • 8
    Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000; 41: 11771189.
  • 9
    Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002; 224: 748756.
  • 10
    Ruers T, Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer. 2002; 38: 10231033.
  • 11
    Saunders TH, Mendes Ribeiro HK, Gleeson FV. New techniques for imaging colorectal cancer: the use of MRI, PET and radioimmunoscintigraphy for primary staging and follow-up. Br Med Bull. 2002; 64: 8199.
  • 12
    Zealley IA, Skehan SJ, Rawlinson J, Coates G, Nahmias C, Somers S. Selection of patients for resection of hepatic metastases: improved detection of extrahepatic disease with FDG pet. Radiographics. 2001; 21(Spec no):S55S69.
  • 13
    Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Biochem. 2003; 36: 27.
  • 14
    Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem. 2003; 49: 718.
  • 15
    Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001; 285: 19871991.
  • 16
    Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. Aust NZ J Surg. 2003; 73: 712716.
  • 17
    Arulampalam T, Costa D, Visvikis D, Boulos P, Taylor I, Ell P. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur J Nucl Med. 2001; 28: 17581765.
  • 18
    Beets G, Penninckx F, Schiepers C, et al. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg. 1994; 81: 16661670.
  • 19
    Boykin KN, Zibari GB, Lilien DL, McMillan RW, Aultman DF, McDonald JC. The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver. Am Surg. 1999; 65: 11831185.
  • 20
    Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997; 38: 11961201.
  • 21
    Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr., Pinson CW. Evaluation of benign versus malignant hepatic lesions with positron emission tomography. Arch Surg. 1998; 133: 510515.
  • 22
    Desai DC, Zervos EE, Arnold MW, Burak WE Jr., Mantil J, Martin EW Jr. Positron emission tomography affects surgical management in recurrent colorectal cancer patients. Ann Surg Oncol. 2003; 10: 5964.
  • 23
    Flamen P, Stroobants S, Van Cutsem E, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol. 1999; 17: 894901.
  • 24
    Flamen P, Hoekstra OS, Homans F, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer. 2001; 37: 862869.
  • 25
    Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg. 1998; 227: 319223.
  • 26
    Fong Y, Saldinger PF, Akhurst T, et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg. 1999; 178: 282287.
  • 27
    Hung GU, Shiau YC, Tsai SC, Chao TH, Ho YJ, Kao CH. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res. 2001; 21: 13751378.
  • 28
    Imbriaco M, Akhurst T, Hilton S, et al. Whole-body FDG-PET in patients with recurrent colorectal carcinoma. A comparative study with CT. Clin Positron Imaging. 2000; 3: 107114.
  • 29
    Imdahl A, Reinhardt MJ, Nitzsche EU, et al. Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg. 2000; 385: 129134.
  • 30
    Iwata Y, Shiomi S, Sasaki N, et al. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med. 2000; 14: 121126.
  • 31
    Johnson K, Bakhsh A, Young D, Martin TE Jr., Arnold M. Correlating computed tomography and positron emission tomography scan with operative findings in metastatic colorectal cancer. Dis Colon Rectum. 2001; 44: 354357.
  • 32
    Lai DT, Fulham M, Stephen MS, et al. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg. 1996; 131: 703707.
  • 33
    Langenhoff BS, Oyen WJ, Jager GJ, et al. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol. 2002; 20: 44534458.
  • 34
    Lonneux M, Reffad AM, Detry R, Kartheuser A, Gigot JF, Pauwels S. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2002; 29: 915921.
  • 35
    Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol. 1997; 4: 613620.
  • 36
    Rohren EM, Paulson EK, Hagge R, et al. The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. Clin Nucl Med. 2002; 27: 550555.
  • 37
    Ruers TJ, Langenhoff BS, Neeleman N, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol. 2002; 20: 388395.
  • 38
    Rydzewski B, Dehdashti F, Gordon BA, Teefey SA, Strasberg SM, Siegel BA. Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET. AJR Am J Roentgenol. 2002; 178: 353358.
  • 39
    Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol. 1995; 21: 517522.
  • 40
    Simo M, Lomena F, Setoain J, et al. FDG-PET improves the management of patients with suspected recurrence of colorectal cancer. Nucl Med Commun. 2002; 23: 975982.
  • 41
    Staib L, Schirrmeister H, Reske SN, Beger HG. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg. 2000; 180: 15.
  • 42
    Strasberg SM, Siegal BA. Survival of patients staged by FDG-PET before resection of hepatic metastases from colorectal cancer [letter]. Ann Surg. 2002; 235: 308.
  • 43
    Topal B, Flamen P, Aerts R, et al. Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases. Eur J Surg Oncol. 2001; 27: 175179.
  • 44
    Valk PE, Abella-Columna E, Haseman MK, et al. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999; 134: 503511.
  • 45
    Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg. 1996; 171: 2126.
  • 46
    Whiteford MH, Whiteford HM, Yee LF, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum. 2000; 43: 759767.
  • 47
    Yasuda S, Makuuchi Y, Sadahiro S, et al. Colorectal cancer recurrence in the liver: detection by PET. Tokai J Exp Clin Med. 1998; 23: 167171.
  • 48
    Zhuang H, Sinha P, Pourdehnad M, Duarte PS, Yamamoto AJ, Alavi A. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med Commun. 2000; 21: 793798.
  • 49
    Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg. 2001; 233: 293299.